본문 바로가기

US · 21 CFR

21 CFR 4.103

What information must you share with other constituent part applicants for the combination product?

21 CFR Part 4 › Subpart B—Postmarketing Safety Reporting for Combination Products

조항 원문

(a) When you receive information regarding an event that involves a death or serious injury as described in § 803.3 of this chapter, or an adverse experience as described in § 314.80(a) of this chapter or § 600.80(a) of this chapter, associated with the use of the combination product, you must provide the information to the other constituent part applicant(s) for the combination product no later than 5 calendar days of your receipt of the information.

(b) With regard to information you must provide to the other constituent part applicant(s) for the combination product, you must maintain records that include:

(1) A copy of the information you provided,

(2) The date the information was received by you,

(3) The date the information was provided to the other constituent part applicant(s), and

(4) The name and address of the other constituent part applicant(s) to whom you provided the information.

본문은 원문(영어)입니다. 국문 번역은 준비 중입니다.

출처: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · 수집일 2026-11-16

Weekly Newsletter

FDA·EU·식약처 실사 지적, 매주 받아 보세요

FDA·EMA·식약처의 새 지적과 조치를 공식 원문 링크와 함께 보내드립니다. 사이트에 새로운 기능이 생기면 함께 안내드립니다. 구독은 언제든 한 번의 클릭으로 해지할 수 있습니다.

이번 주 소식 먼저 보기

확인 메일의 버튼을 누르면 구독이 완료됩니다 · 언제든 해지할 수 있습니다